The protective effects of DA-9801 (Dioscorea extract) on the peripheral nerves in streptozotocin-induced diabetic rats

Journal of Nutritional Science and Vitaminology

Volumn 59, Issue 5, 2013, Pages 437-446

  Lee, Kyung Ae ^a   Jin, Heung Yong ^a   Baek, Hong Sun ^a   Park, Tae Sun ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

DA 9801; Diabetic peripheral neuropathy; Nerve growth factor; Neuroprotective effect

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DIETARY SUPPLEMENTS; GASTRIC MUCOSA; KIDNEY CORTEX; MALE; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; PAIN THRESHOLD; PERIPHERAL NERVOUS SYSTEM; PLANT EXTRACTS; PLANT PREPARATIONS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; SKIN; STREPTOZOCIN;

EID: 84892588906     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.59.437     Document Type: Article

References (28)

1. Tesfaye S. 2011. Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Diabetes Investig 2: 33-42.
2. Vinik AI, Park TS, Stansberry KB, Pittenger GL. 2000. Diabetic neuropathies. Diabetologia 43: 957-973.
3. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. 2004. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 21: 114-121.
4. Hellweg R, Raivich G, Hartung HD, Hock C, Kreutzberg GW. 1994. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 130: 24-30.
5. Anand P, Terenghi G, Warner G, Kopelman P, Williams-Chestnut RE, Sinicropi DV. 1996. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat Med 2: 703-707.
6. Apfel SC. 1999. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 41 (Suppl 1): 27-34.
7. Colangelo AM, Bianco MR, Vitagliano L, Cavaliere C, Cirillo G, De Gioia L. 2008. A new nerve growth factormimetic peptide active on neuropathic pain in rats. J Neurosci 28: 2698-2709.
8. Kwon CS, Sohn HY, Kim SH, Kim JH, Son KH, Lee JS. 2003. Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents. Biosci Biotechnol Biochem 67: 1451-1456.
9. Ma C, Wang W, Chen YY, Liu RN, Wang RF, Du LJ. 2005. Neuroprotective and antioxidant activity of compounds from the aerial parts of Dioscorea opposita. J Nat Prod 68: 1259-1261.
10. Kang TH, Choi SZ, Lee TH. 2008. Characteristics of antidiabetic effect of Dioscorea rhizome (1)-Hypoglycemic effect. Korean J Food Nutr 21: 425-429.
11. Kang TH, Choi SZ, Lee TH. 2008. Characteristics of antidiabetic effect of Dioscorea rhizome (2)-Prevention of diabetic neuropathy by NGF induction. Korean J Food Nutr 21: 430-435.
12. Kang TH, Moon E, Hong BN, Choi SZ, Son M, Park JH. 2011. Diosgenin from Dioscorea nipponica ameliorates diabetic neuropathy by inducing nerve growth factor. Biol Pharm Bull 34: 1493-1498.
13. Kim KH, Kim MA, Moon EJ, Kim SY, Choi SZ, Son MW, Lee KR. 2011. Furostanol saponins from the rhizomes of Dioscorea japonica and their effects on NGF induction. Bioorg Med Chem Lett 21: 2075-2078.
14. Kim N, Kim SH, Kim YJ, Kim JK, Nam MK, Rhim H. 2011. Neurotrophic activity of DA-9801, a mixture extract of Dioscorea japonica Thunb. and Dioscorea nipponica Makino, in vitro. J Ethnopharmacol 137: 312-319.
15. Choi SZ, Son MW. 2011. Novel botanical drug for the treatment of diabetic neuropathy. Arch Pharm Res 34: 865-867.
16. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. 1994. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
17. Zor T, Selinger Z. 1996. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem 236: 302-308.
18. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. 2009. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 40: 536-544.
19. Asensio-Pinilla E, Udina E, Jaramillo J, Navarro X. 2009. Electrical stimulation combined with exercise increase axonal regeneration after peripheral nerve injury. Exp Neurol 219: 258-265.
20. Brownlee M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
21. Giugliano D, Ceriello A, Paolisso G. 1996. Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267.
22. Pittenger G, Vinik AI. 2003. Nerve growth factor and diabetic neuropathy. Exp Diabetes Res 4: 271-285.
23. Kakinoki B, Sekimoto S, Yuki S, Ohgami T, Sejima M, Yamagami K. 2006. Orally active neurotrophin-enhancing agent protects against dysfunctions of the peripheral nerves in hyperglycemic animals. Diabetes 55: 616-621.
24. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. 1998. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51: 695-702.
25. Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M. 2000. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284: 2215-2221.
26. Kim MJ, Kim HN, Kang KS, Baek NI, Kim DK, Kim YS. 2004. Methanol extract of Dioscoreae Rhizoma inhibits pro-inflammatory cytokines and mediators in the synoviocytes of rheumatoid arthritis. Int Immunopharmacol 4: 1489-1497.
27. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P. 2010. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33: 2285-2293.
28. Tesfaye S, Selvarajah D. 2012. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 28 (Suppl 1): 8-14.